Michael P. Rettig

7.3k total citations
122 papers, 3.5k citations indexed

About

Michael P. Rettig is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Michael P. Rettig has authored 122 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hematology, 53 papers in Oncology and 36 papers in Immunology. Recurrent topics in Michael P. Rettig's work include Hematopoietic Stem Cell Transplantation (41 papers), Acute Myeloid Leukemia Research (32 papers) and CAR-T cell therapy research (28 papers). Michael P. Rettig is often cited by papers focused on Hematopoietic Stem Cell Transplantation (41 papers), Acute Myeloid Leukemia Research (32 papers) and CAR-T cell therapy research (28 papers). Michael P. Rettig collaborates with scholars based in United States, Australia and Chile. Michael P. Rettig's co-authors include John F. DiPersio, Geoffrey L. Uy, Julie Ritchey, Ravi Vij, Peter Westervelt, Philip S. Low, Matthew Holt, Pablo Ramírez, Amanda F. Cashen and Gary Bridger and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Michael P. Rettig

118 papers receiving 3.5k citations

Peers

Countries citing papers authored by Michael P. Rettig

Since Specialization

Citations

This map shows the geographic impact of Michael P. Rettig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Rettig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Rettig more than expected).

Fields of papers citing papers by Michael P. Rettig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Rettig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Rettig. The network helps show where Michael P. Rettig may publish in the future.

Co-authorship network of co-authors of Michael P. Rettig

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Rettig. A scholar is included among the top collaborators of Michael P. Rettig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Rettig. Michael P. Rettig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) 2024 ·Transplantation and Cellular Therapy ·Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, (unknown), Rawan Faramand, Ryan J. Mattison, Michael P. Rettig, Kenneth Jacobs, Ouiam Bakkacha, John Muth, (unknown), (unknown), (unknown), (unknown), Matthew Cooper, Jan Davidson‐Moncada, John F. DiPersio	1
2	Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization 2024 ·Blood Advances ·Daniel Cancilla, Michael P. Rettig, Darja Karpova, (unknown), Megh Singh, Marvin J. Meyers, Peter Ruminski, Stephanie Christ, Ezhilarasi Chendamarai, Feng Gao, Leah Gehrs, Julie Ritchey, Michael J. Prinsen, John F. DiPersio	7
3	A simplified G-CSF–free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model 2024 ·Blood Advances ·Chang Li, (unknown), Peter Ruminski, Michael P. Rettig, Darja Karpova, Hans‐Peter Kiem, John F. DiPersio, André Lieber	7
4	Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study 2024 ·Blood ·Zachary Crees, Michael P. Rettig, Reyka G. Jayasinghe, Stephanie Christ, Feng Gao, (unknown), Sana Rehman, Suzanne R. Thibodeaux, Ella Sorani, Allison A. King, John F. DiPersio	2
5	Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma 2023 ·Blood Advances ·Armin Ghobadi, (unknown), (unknown), Michael P. Rettig, Amanda F. Cashen, Leah Gehrs, Stephanie Christ, (unknown), Nicholas A. Wallace, Julie Ritchey, Neha Mehta–Shah, Peter Westervelt, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, John F. DiPersio	6
6	Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization 2023 ·Blood ·Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie Ritchey, John F. DiPersio	1
7	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud, Feng Gao, Michael P. Rettig, (unknown), Leah Gehrs, Nicholas A. Wallace, Camille N. Abboud, Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matthew Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder	1
8	Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation 2021 ·Journal of Clinical Investigation ·Stephen P. Persaud, Julie Ritchey, Sena Kim, (unknown), Peter Ruminski, Matthew Cooper, Michael P. Rettig, Jaebok Choi, John F. DiPersio	15
9	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS 2021 ·Leukemia Research ·(unknown), Michael P. Rettig, (unknown), Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoffrey L. Uy, Stephen Marcus, Peter Westervelt	14
10	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival 2020 ·Clinical Cancer Research ·Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, (unknown), Mark A. Fiala, Julie O’Neal, (unknown), Julie Ritchey, Michael P. Rettig, (unknown), Steven Fletcher, Ravi Vij, John F. DiPersio, Gregory M. Lanza	19
11	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product 2018 ·Blood ·Michael P. Rettig, Geoffrey L. Uy, Asad Bashey, Steven M. Devine, Samantha Jaglowski, (unknown), Ella Sorani, (unknown), Osnat Bohana‐Kashtan, Stephen Shaw, Peter Westervelt, John F. DiPersio	1
12	AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia 2018 ·Blood ·Linda Eissenberg, Julie Ritchey, Michael P. Rettig, Judith A. Fox, Jeanmarie Guenot, John F. DiPersio	4
13	Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies 2017 ·Blood ·Michael P. Rettig, John E. Godwin, Norbert Vey, Bernard A. Fox, Carmen Ballesteros‐Merino, Carlo Bifulco, Daner Li, (unknown), (unknown), Jichao Sun, Hélène Lelièvre, Jan Baughman, (unknown), John Muth, Paul A. Moore, Ezio Bonvini, Jon M. Wigginton, John F. DiPersio, Jan Davidson‐Moncada	10
14	Preclinical Development of CD38-Targeted [⁸⁹Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma 2017 ·Journal of Nuclear Medicine ·Anchal Ghai, (unknown), Nicholas S. Cho, Chantiya Chanswangphuwana, Michael P. Rettig, Duanwen Shen, John F. DiPersio, Walter J. Akers, Farrokh Dehdashti, Samuel Achilefu, Ravi Vij, Monica Shokeen	47
15	Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated 2016 ·Biology of Blood and Marrow Transplantation ·Ramzi Abboud, Jesse Keller, Michael Slade, John F. DiPersio, Peter Westervelt, Michael P. Rettig, Stéphanie Meier, Todd A. Fehniger, Camille N. Abboud, Geoffrey L. Uy, Ravi Vij, Kathryn Trinkaus, Mark A. Schroeder, Rizwan Romee	104
16	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia 2012 ·Blood ·Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi, Kyle McFarland, Kathryn Trinkaus, Lindsay Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio	310
17	Preclinical evaluation of Mab CC188 for ovarian cancer imaging 2011 ·International Journal of Cancer ·Man Xu, Michael P. Rettig, (unknown), Binbin Wang, Walter J. Akers, Di Cao, David G. Mutch, John F. DiPersio, Samuel Achilefu	11
18	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction 2008 ·Blood ·Steven M. Devine, Ravi Vij, Michael P. Rettig, Laura Todt, (unknown), Nicholas M. Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio	234
19	Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull mice 2007 ·Experimental Hematology ·Bruno Nervi, Michael P. Rettig, Julie Ritchey, Hanlin L. Wang, Gerhard Bauer, Jon Walker, Mark Bonyhadi, Ronald Berenson, Julie L. Prior, David Piwnica‐Worms, Jan A. Nolta, John F. DiPersio	52
20	Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease 2003 ·Molecular Therapy ·Michael P. Rettig, Julie Ritchey, Todd E. Meyerrose, Jeffrey S. Haug, John F. DiPersio	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact